## Sanjoy K Paul

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7587414/publications.pdf

Version: 2024-02-01

92 papers 13,816 citations

32 h-index 49824 91 g-index

95 all docs 95
docs citations

95 times ranked 14476 citing authors

#	Article	IF	CITATIONS
1	A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes. Journal of Diabetes Research, 2022, 2022, 1-10.	1.0	2
2	Trend in Blood Pressure Control Post Antihypertensive Drug Initiation in the U.S American Journal of Preventive Medicine, 2022, 62, 716-726.	1.6	0
3	Cardiorenal Complications in Young-Onset Type 2 Diabetes Compared Between White Americans and African Americans. Diabetes Care, 2022, 45, 1873-1881.	4.3	4
4	The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically III Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study. Clinical Infectious Diseases, 2021, 72, 1369-1378.	2.9	85
5	Association of Cardiometabolic Multimorbidity and Depression With Cardiovascular Events in Early-Onset Adult Type 2 Diabetes: A Multiethnic Study in the U.S Diabetes Care, 2021, 44, 231-239.	4.3	26
6	The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study. European Heart Journal, 2021, 42, 1728-1738.	1.0	53
7	Temporal trends in coâ€morbidities and cardiometabolic risk factors at the time of type 2 diabetes diagnosis in the <scp>UK</scp> . Diabetes, Obesity and Metabolism, 2021, 23, 1150-1161.	2.2	10
8	Therapeutic inertia in the management of dyslipidaemia and hypertension in incident type 2 diabetes and the resulting risk factor burden: Realâ€world evidence from primary care. Diabetes, Obesity and Metabolism, 2021, 23, 1518-1531.	2.2	10
9	A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis. Blood, 2021, 137, 1970-1979.	0.6	32
10	Association of biological antirheumatic therapy with risk for type 2 diabetes: a retrospective cohort study in incident rheumatoid arthritis. BMJ Open, 2021, 11, e042246.	0.8	2
11	Simulation training in non-cancer palliative care for healthcare workers: a systematic review of controlled studies. BMJ Simulation and Technology Enhanced Learning, 2021, 7, bmjstel-2019-000570.	0.7	2
12	Temporal Trend in Young-Onset Type 2 Diabetesâ€"Macrovascular and Mortality Risk: Study of U.K. Primary Care Electronic Medical Records. Diabetes Care, 2020, 43, 2208-2216.	4.3	24
13	Cardiometabolic risk factor control in black and white people in the United States initiating sodiumâ€glucose coâ€transporterâ€2 inhibitors: A realâ€world study. Diabetes, Obesity and Metabolism, 2020, 22, 2384-2397.	2.2	9
14	Third-Line Antidiabetic Therapy Intensification Patterns and Glycaemic Control in Patients with Type 2 Diabetes in the USA: A Real-World Study. Drugs, 2020, 80, 477-487.	4.9	5
15	Evaluating the Representativeness of US Centricity Electronic Medical Records With Reports From the Centers for Disease Control and Prevention: Comparative Study on Office Visits and Cardiometabolic Conditions. JMIR Medical Informatics, 2020, 8, e17174.	1.3	9
16	A Robust Statistical Approach to Analyse Population Pharmacokinetic Data in Critically III Patients Receiving Renal Replacement Therapy. Clinical Pharmacokinetics, 2019, 58, 263-270.	1.6	0
17	A screen-based simulation training program to improve palliative care of people with advanced dementia living in residential aged care facilities and reduce hospital transfers: study protocol for the IMproving Palliative care Education and Training Using Simulation in Dementia (IMPETUS-D) cluster randomised controlled trial. BMC Palliative Care. 2019. 18. 86.	0.8	12
18	Cardiovascular Risk Factor Burden in People With Incident Type 2 Diabetes in the U.S. Receiving Antidiabetic and Cardioprotective Therapies. Diabetes Care, 2019, 42, 644-650.	4.3	9

#	Article	IF	CITATIONS
19	Selectivity of beta-blockers, cardiovascular and all-cause mortality in people with hypoglycaemia: An observational study. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 481-488.	1.1	3
20	Ethnicity-specific association of BMI levels at diagnosis of type 2 diabetes with cardiovascular disease and all-cause mortality risk. Acta Diabetologica, 2019, 56, 87-96.	1.2	8
21	Treatment with incretins does not increase the risk of pancreatic diseases compared to older antiâ€hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes. Diabetic Medicine, 2019, 36, 491-498.	1.2	9
22	Longâ€term sustainability of glycaemic achievements with secondâ€line antidiabetic therapies in patients with type 2 diabetes: <scp>A</scp> realâ€world study. Diabetes, Obesity and Metabolism, 2018, 20, 1722-1731.	2.2	12
23	Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes. Diabetes Care, 2018, 41, 69-78.	4.3	195
24	Effectiveness of biologic and non-biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: New evidence from real-world data. Seminars in Arthritis and Rheumatism, 2018, 47, 478-484.	1.6	18
25	Weight loss and mortality risk in patients with different adiposity at diagnosis of type 2 diabetes: a longitudinal cohort study. Nutrition and Diabetes, 2018, 8, 37.	1.5	9
26	Prevalence and incidence of complications at diagnosis of T2DM and during follow-up by BMI and ethnicity: a matched case–control analysis. Cardiovascular Diabetology, 2018, 17, 70.	2.7	24
27	The Foot Orthoses versus Hip eXercises (FOHX) trial for patellofemoral pain: a protocol for a randomized clinical trial to determine if foot mobility is associated with better outcomes from foot orthoses. Journal of Foot and Ankle Research, 2017, 10, 5.	0.7	12
28	Comparison of body mass index at diagnosis of diabetes in a multiâ€ethnic population: <scp>A</scp> caseâ€control study with matched nonâ€diabetic controls. Diabetes, Obesity and Metabolism, 2017, 19, 1014-1023.	2.2	45
29	Association between augmented renal clearance and clinical outcomes in patients receiving $\hat{l}^2$ -lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial. International Journal of Antimicrobial Agents, 2017, 49, 624-630.	1.1	80
30	Comparative effectiveness and safety of different basal insulins in a realâ€world setting. Diabetes, Obesity and Metabolism, 2017, 19, 1116-1126.	2.2	11
31	Do glycoalbumin levels preferentially reflect changes in postprandial glucose excursions?. Diabetic Medicine, 2017, 34, 1284-1290.	1.2	2
32	The serum protein responses to treatment with Xiaoke Pill and Glibenclamide in type 2 diabetes patients. Clinical Proteomics, 2017, 14, 19.	1.1	8
33	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 877-886.	5.5	245
34	Addition of or switch to insulin therapy in people treated with glucagonâ€like peptideâ€1 receptor agonists: A realâ€world study in 66 583 patients. Diabetes, Obesity and Metabolism, 2017, 19, 108-117.	2.2	32
35	Rationale, Design, and Baseline Characteristics of Beijing Prediabetes Reversion Program: A Randomized Controlled Clinical Trial to Evaluate the Efficacy of Lifestyle Intervention and/or Pioglitazone in Reversion to Normal Glucose Tolerance in Prediabetes. Journal of Diabetes Research, 2017. 1-11.	1.0	12
36	Data Mining Approach to Estimate the Duration of Drug Therapy from Longitudinal Electronic Medical Records. Open Bioinformatics Journal, 2017, 10, 1-15.	1.0	14

#	Article	IF	Citations
37	Data Mining Approach to Identify Disease Cohorts from Primary Care Electronic Medical Records: A Case of Diabetes Mellitus. Open Bioinformatics Journal, 2017, 10, 16-27.	1.0	21
38	Comparison of trajectories of selfâ€monitored glucose levels by hypoglycemia status over 52 weeks of treatment with insulin glargine or exenatide once weekly. Journal of Diabetes, 2016, 8, 148-157.	0.8	3
39	Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes, Obesity and Metabolism, 2016, 18, 401-409.	2.2	207
40	Weight gain in insulinâ€treated patients by body mass index category at treatment initiation: <scp>n</scp> ew evidence from realâ€world data in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2016, 18, 1244-1252.	2.2	34
41	Genetic and Clinical Predictive Factors of Sulfonylurea Failure in Patients with Type 2 Diabetes. Diabetes Technology and Therapeutics, 2016, 18, 586-593.	2.4	8
42	Single institution retrospective review of perioperative chemotherapy in adult and adolescent patients with operable osteosarcoma. Asia-Pacific Journal of Clinical Oncology, 2016, 12, e222-e228.	0.7	8
43	SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients. BMC Infectious Diseases, 2016, 16, 103.	1.3	14
44	Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. Journal of Antimicrobial Chemotherapy, 2016, 71, 196-207.	1.3	129
45	Association of smoking and concomitant metformin use with cardiovascular events and mortality in people newly diagnosed with type 2 diabetes. Journal of Diabetes, 2016, 8, 354-362.	0.8	14
46	A Bayesian Modelling Approach with Balancing Informative Prior for Analysing Imbalanced Data. PLoS ONE, 2016, 11, e0152700.	1.1	4
47	Promoting Activity in Geriatric Rehabilitation: A Randomized Controlled Trial of Accelerometry. PLoS ONE, 2016, 11, e0160906.	1.1	35
48	Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovascular Diabetology, 2015, 14, 100.	2.7	206
49	Dynamic risk factors associated with nonâ€severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly ä¸Žæ¯æ—¥ä¸€æ¬¡ä½¿ç"¨ç"¯ç²¾èf°å²›ç´æ^–者æ¯å"一次使用艾塞€	e,£ <b>e,</b> ½æ²>	∘ç <del>_8</del> _çš"æ,£
50	Orthosis-Shaped Sandals Are as Efficacious as In-Shoe Orthoses and Better than Flat Sandals for Plantar Heel Pain: A Randomized Control Trial. PLoS ONE, 2015, 10, e0142789.	1.1	9
51	Evaluation of Perioperative Predictors of Acute Kidney Injury Post Orthotopic Liver Transplantation. Anaesthesia and Intensive Care, 2015, 43, 757-763.	0.2	13
52	Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype–positive rheumatoid arthritis patients. Science Translational Medicine, 2015, 7, 290ra87.	5.8	302
53	Validity Study of Video Teleconsultation for the Management of Diabetes: A Pilot Randomized Controlled Trial. Diabetes Technology and Therapeutics, 2015, 17, 717-725.	2.4	12
54	A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1298-1305.	2.5	206

#	Article	IF	CITATIONS
55	The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study. Cardiovascular Diabetology, 2015, 14, 10.	2.7	51
56	Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. Trials, 2015, 16, 24.	0.7	57
57	Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. Diabetes Care, 2015, 38, 316-322.	4.3	276
58	Predicting Upcoming Glucose Levels in Patients with Type 1 Diabetes Using a Generalized Autoregressive Conditional Heteroscedasticity Modelling Approach. International Journal of Statistics in Medical Research, 2015, 4, 188-198.	0.5	5
59	The Association between Body Mass Index and Mortality in Incident Dialysis Patients. PLoS ONE, 2014, 9, e114897.	1.1	37
60	Obesity paradox in people newly diagnosed with type 2 diabetes with and without prior cardiovascular disease. Diabetes, Obesity and Metabolism, 2014, 16, 317-325.	2.2	47
61	DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current Â-Lactam Antibiotic Doses Sufficient for Critically III Patients?. Clinical Infectious Diseases, 2014, 58, 1072-1083.	2.9	843
62	Reply to Rhodes et al. Clinical Infectious Diseases, 2014, 59, 907-908.	2.9	2
63	Cardiovascular disease is increased prior to onset of rheumatoid arthritis but not osteoarthritis: the population-based Nord-Trøndelag health study (HUNT). Arthritis Research and Therapy, 2014, 16, R85.	1.6	13
64	Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. American Heart Journal, 2013, 166, 983-989.e7.	1.2	116
65	Severe hypoglycaemia requiring emergency medical assistance by ambulance services in the East Midlands: A retrospective study. Primary Care Diabetes, 2013, 7, 159-165.	0.9	39
66	Trajectory of intensive treat-to-target disease modifying drug regimen in an observational study of an early rheumatoid arthritis cohort. BMJ Open, 2013, 3, e003083.	0.8	10
67	All-cause mortality in relation to glycated haemoglobin in individuals with newly diagnosed type 2 diabetes: a retrospective cohort study. British Journal of Diabetes and Vascular Disease, 2013, 13, 22-30.	0.6	1
68	Interaction of serum ferritin and body mass index in patients with chronic hepatitis B: Improved prediction of cirrhosis. Hepatology, 2013, 57, 2094-2095.	3.6	1
69	Efficacy and Safety of Traditional Chinese Medicine for Diabetes: A Double-Blind, Randomised, Controlled Trial. PLoS ONE, 2013, 8, e56703.	1.1	71
70	Screening for delirium within the interral acute care assessment system. Journal of Nutrition, Health and Aging, 2012, 16, 695-700.	1.5	20
71	Women develop type 2 diabetes at a higher body mass index than men. Diabetologia, 2012, 55, 1556-1557.	2.9	57
72	WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation. Leukemia Research, 2012, 36, 453-458.	0.4	26

#	Article	IF	CITATIONS
73	A phase <scp>II</scp> study of riskâ€ødapted intravenous melphalan in patients with <scp>AL</scp> amyloidosis. British Journal of Haematology, 2012, 157, 766-769.	1.2	9
74	Effects of HbA $<$ sub $>$ 1c $<$ /sub $>$ and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide $<$ sup $>$ * $<$ /sup $>$ . Diabetes, Obesity and Metabolism, 2012, 14, 826-834.	2.2	15
75	Incorporating teledermatology into emergency medicine. EMA - Emergency Medicine Australasia, 2011, 23, 562-568.	0.5	35
76	Interleukin- $1\hat{l}^2$ Produced in Response to Islet Autoantigen Presentation Differentiates T-Helper 17 Cells at the Expense of Regulatory T-Cells. Diabetes, 2011, 60, 248-257.	0.3	33
77	Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: A randomised placebo controlled factorial trial. Atherosclerosis, 2010, 213, 512-517.	0.4	24
78	Effect of educational outreach on general practice prescribing of antibiotics and antidepressants: A two-year randomised controlled trial. Scandinavian Journal of Primary Health Care, 2009, 27, 195-201.	0.6	16
79	Predicting 6-Year Mortality Risk in Patients With Type 2 Diabetes: Response to Wells et al Diabetes Care, 2009, 32, e60-e60.	4.3	1
80	Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial. Diabetologia, 2009, 52, 50-59.	2.9	70
81	Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia, 2009, 52, 2288-2298.	2.9	1,033
82	Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. New England Journal of Medicine, 2009, 361, 1736-1747.	13.9	608
83	Impact of comorbid diabetes on quality of life and perception of angina pain in people with angina registered with general practitioners in the UK. Quality of Life Research, 2008, 17, 887-894.	1.5	7
84	Predictability of price of tea from sensory assessments and biochemical information using data-mining techniques. Journal of the Science of Food and Agriculture, 2008, 88, 1354-1362.	1.7	6
85	10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine, 2008, 359, 1577-1589.	13.9	6,543
86	Cost-effectiveness of a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care. Heart, 2008, 94, 1601-1606.	1,2	42
87	Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes. New England Journal of Medicine, 2008, 359, 1565-1576.	13.9	674
88	Analysis of bedside entertainment services' effect on post cardiac surgery physical activity: a prospective, randomised clinical trial. European Journal of Cardio-thoracic Surgery, 2008, 34, 1022-1026.	0.6	16
89	Disease management programme for secondary prevention of coronary heart disease and heart failure in primary care: a cluster randomised controlled trial. Heart, 2007, 93, 1398-1405.	1.2	65
90	Factors predictive of voiding problems following insertion of tension-free vaginal tape. International Journal of Gynecology and Obstetrics, 2007, 96, 122-126.	1.0	12

## Sanjoy K Paul

#	Article	IF	CITATIONS
91	Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. New England Journal of Medicine, 2007, 357, 1716-1730.	13.9	651
92	Cardiac baroreceptor sensitivity: A prognostic marker in predialysis chronic kidney disease patients?. Kidney International, 2005, 67, 1019-1027.	2.6	16